Covenant Asset Management’s United Therapeutics UTHR Stock Holding History

Covenant Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,010	Closed	-$3.14M	–	174
2023 Q1	$3.14M	Sell	14,010 -138	-1%	-$34K	0.75%	43
2022 Q4	$3.93M	Sell	14,148 -150	-1%	-$37.9K	0.94%	37
2022 Q3	$2.99M	Buy	14,298 +7,408	+108%	+$1.66M	0.85%	36
2022 Q2	$1.62M	Buy	+6,890	New	+$1.4M	0.52%	66

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Covenant Asset Management's UTHR Position: Q2 2023 in Review

Covenant Asset Management sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 14,010 shares — an estimated $3.14M sold.

Covenant Asset Management first reported a position in UTHR in Q2 2022 and held it in 4 quarters. The position peaked at $3.93M in Q4 2022. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Covenant Asset Management reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Covenant Asset Management sold 14,010 United Therapeutics shares in Q2 2023, an estimated $3.14M.
Covenant Asset Management first reported a position in United Therapeutics in Q2 2022 and held it in 4 quarters.
Covenant Asset Management's United Therapeutics position peaked at $3.93M in Q4 2022.
473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Covenant Asset Management's 13F filing for Q2 2023, filed 12 Jul 2023.